05 Jul 2016 | Fujirebio Europe launches a communication campaign to help explain the advantage of early diagnosis of Alzheimer's Disease

Gent, Belgium: July 5th 2016 - Fujirebio Europe has launched a communication campaign under the title "A few drops of insight can lead to an ocean of understanding" intended to help doctors, nurses and healthcare workers explain to patients and their families the advantages of an early diagnosis of Alzheimer's Disease through CSF (Cerebrospinal fluid) testing.

With modern in vitro diagnostics it is possible to detect Alzheimer’s Disease with great certainty at a very early stage. This neurodegenerative disease starts developing in the brain a long time before its first symptoms start to show. Early detection can make a tremendous difference for the patient.

The campaign consists of a website, www.alzheimer-clarity.info notably containing an educational video, a patient leaflet with typical questions and answers around CSF testing, and a campaign poster intended to bring attention to the campaign in waiting rooms.

The campaign is launched in English and French for the moment but is going through translation into German, Italian, Spanish and Portugese.

Please contact Fujirebio Europe for more details or if you are interested in using the campaign material in your region.

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.